Two oral therapeutics specialists bag a combined $140M via IPO, VC funding

Although fancy technology is a big draw in drug delivery, the simple pill holds allure, at least as a replacement for dreaded needles or cumbersome intravenous infusions. Chiasma sold 1 million more shares than it originally planned en route to an IPO that raised $102 million. The developer of oral drugs to treat orphan diseases that are being treated by injectables sold 6.4 million shares for $16, above the expected price range. And Protagonist Therapeutics, the developer of an oral peptide drug aimed at irritable bowel disease, just completed a $40 million VC round, which included life science investment firms and strategic players J&J Innovation and Lilly Ventures. More about Chiasma's IPO | More about Protagonist Therapeutics from FierceBiotech

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.